WELCOME TO Million Health Pharmaceuticals


Viroclear-Dalsiclear tablet has two component Sofosbuvir & Daclatasvir Sofosbuvir: Sofosbuvir is a prohibitor of nucleotide analogue, especially prohibits HCV non-structural protein 5B RNA dependent RNA polymerase. Sofosbuvir undergo intracellular metabolism, which produce pharmacologically active compound like uridine analog triphosphate. Sofosbuvir interceded into RNA of hepatitis C virus with the help of NS5B polymerase. This may acts as chain eliminator. Daclatasvir: Non structural 5A protein is essential for viral multiplication. Daclatasvir interfere with the activity of NS5A protein, this may leads to viral eradication.



The maximum peak plasma concentration time of Daclatasvir reaches within 2 hours; whereas sofosbuvir attains at 0.5 to 2 hours after the dose. There is no effect occurred while taking Viroclear-Dalsiclear tablet with or without meal. The mean bioavailability of Daclatasvir is reaches at 67%


Nearly 99% of drug Daclatasvir is highly bound to human plasma protein; whereas sofosbuvir has relatively 61 to 65% protein bounding capacity. Volume of distribution of Daclatasvir is 47L


Daclatasvir is a CYP3A substrate, which is essential for metabolism of Daclatasvir. Sofosbuvir undergo hepatic metabolism, it may turns to active metabolite like uridine triphosphate required for anti-viral activity. Metabolism of sofosbuvir leads with the help of carboxyl esterase 1 or cathepsin A.


The elimination of Viroclear-Dalsiclear tablet occurs through urine; feces or exhaled air. Sofosbuvir: 80% in urine; 14% in feces & 2.5% in exhaled air Daclatasvir: 88% in feces; 6.6% in urine


Brand : Viroclear-Dalsiclear
Ingredients : Sofosbuvir + Daclatasvir Dihydrochloride
Strength : 400mg & 60 mg
Manufactured : Abbott
Package : 28 tablets

Dosing consideration

Before staring the treatment with Viroclear-Dalsiclear tablet, patient may examine periodically by taking hepatic function test and analysis the lab values. Examine HBV infection by counting hepatitis B surface antigen & hepatitis B core antibody.

Dosage recommendation

The usual dose of Viroclear-Dalsiclear tablet is one tablet should be taken as a single dose by administering with food or without food. On severe condition, Viroclear-Dalsiclear must be combine with ribavirin. The initial dose of ribavirin is 600mg as a single dose, elevating dose up to 1000mg administrated for In HCV genotype I or III patients with decompensated cirrhosis or post transplantation.

The initial dose of ribavirin should be calculated on the basis of body weight of the suspected patients having with compensated cirrhosis; In patient with weight of at least 75kg: 1200mg of ribavirin should be considered. In patient with weight of less than 75kg: 1000mg of ribavirin should be used.

In genotype I

The dose of Viroclear-Dalsiclear is one tablet should be taken with or without food as a single dose given for Patient suffered without cirrhosis & compensated cirrhosis: In decompensated cirrhosis or post liver transplantation: The recommended dose of Viroclear-Dalsiclear is one tablet to be taken as a single dose by combining with ribavirin on weight basis manner.

In genotype III

Patient struggling without cirrhosis: The usual dose of Viroclear-Dalsiclear is one tablet to be taken as a single dose. : The usual dose is one Viroclear-Dalsiclear tablet should be combined with ribavirin as a single dose is given for Patient with compensated, decompensated cirrhosis or post liver transplantation While receiving ribavirin, patient must be administered food. Ribavirin should be taken as twice daily.

Side effects

Side effects occurred in Viroclear-Dalsiclear tablet receiving patients such as; Fatigue Headache Insomnia Nausea Pruritus Asthenia Anemia Loss of appetite Flu like syndrome Pyrexia Diarrhea Rash Neutropenia Myalgia Irritability Pancytopenia Increase of creatine kinase, bilirubin, lipase, AST & ALT HBV reoccurrence may occurs Serious bradycardia while combining with amiodarone

Safety measures taken while undergoing Viroclear-Dalsiclear therapy

Use with caution in the patients are suspected with HBV infection, there is a chance of increasing the risk of HBV reoccurrence in the patient co infected with HCV & HBV Severe bradycardia occurs while concomitant use of Viroclear-Dalsiclear with amiodarone Exposure of loss of therapeutic effect occurs while concurrently use Viroclear-Dalsiclear tablet with P-gp inducers or inhibitors Severe adverse effects may occur due to drug interaction, to prevent this problem avoid this type of combinational therapy.


Viroclear-Dalsiclear may interact with some drugs

Viroclear-Dalsiclear comprising of two prime component like sofosbuvir & Daclatasvir; Sofosbuvir is a P-gp or BCRP drug transporter substrate, while combining Viroclear-Dalsiclear tablet with P-gp inducers causes decreasing the plasma concentration of sofosbuvir. This may results as loss of therapeutic effect. Daclatasvir is a CYP3A substrate, while taking Viroclear-Dalsiclear tablet with CYP3A strong inducers may causes loss of therapeutic effect of Daclatasvir.

Interaction of Viroclear-Dalsiclear with drugs inhibits the CYP3A may elevates the plasma level of Daclatasvir Interaction with warfarin and Viroclear-Dalsiclear tablets Alteration in INR or pro thrombin time may occur in patient Viroclear-Dalsiclear tablet interaction with P-gp or BCRP inhibitors, may leads to cause prolonging the adverse effects of these substrates. Viroclear-Dalsiclear tablet combined with protease inhibitors causes elevating the effect of concentration of Daclatasvir

Viroclear-Dalsiclear tablets are concurrently used with non-nucleoside reverse transcriptase inhibitor causes reducing the effect of concentration of Daclatasvir Viroclear-Dalsiclear tablet combined with amiodarone causes severe bradycardia. Viroclear-Dalsiclear tablets are concomitantly used with lipid lowering drugs causes increasing concentration of these drugs. Viroclear-Dalsiclear tablet combined with anti-convulsants, anti-mycobacterials or herbal products like st. Johns wort causes decreasing the effect of concentration of sofosbuvir.

abdominal pain
abdominal pain
concluded as death
concluded as death
dark urine
dark urine
flu like syndrome
flu like syndrome
loss of apetite
loss of apetite
loss of weight
loss of weight

Quick Contact

Prescription upload

Top Products


Millionpharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Millionpharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Millionpharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Millionpharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Millionpharma.com

At Millionpharma.com , a Caregiver can order prescription medicines on your behalf.


This information should not be used to decide whether or not to take this Product or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this Product . It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this product.